Medicare Part D coverage of GLP-1s could raise costs by $48B

(By: Alexandra Murphy for Becker’s Hospital Review)

Medicare coverage of obesity medications could drive a substantial rise in healthcare spending, according to a new study.

A microsimulation model published in JAMA Health Forum projected that Medicare expenditures would increase by $47.7 billion over 10 years if drugs such as Wegovy and Zepbound were covered under Medicare Part D. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.